Amyris Biotechnologies Obtains $41,750,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=87a5f266-29ca-4da6-9cf6-f1b49a40e2cb&Preview=1 -
Date
10/1/2009 -
Company Name
Amyris Biotechnologies -
Mailing Address
5885 Hollis Street Emeryville, CA 94608 -
Company Description
Amyris Biotechnologies is leveraging breakthroughs in synthetic biology to provide a consistent, cost-effective supply of high-value natural compounds for large and diverse markets, including pharmaceuticals, fine chemicals, nutraceuticals, vitamins, and flavors. Applying advances in molecular biology, we are engineering microbes capable of producing bioactive chemical compounds that are currently available only in limited quantities. This process, developed in the laboratory of Amyris’ founding scientist, Professor Jay Keasling at the University of California, Berkeley, gives us access to compounds unattainable by conventional chemical synthesis and eliminates the challenges associated with harvesting chemicals from natural sources. -
Website
http://www.amyris.com -
Transaction Type
Venture Equity -
Transaction Amount
$41,750,000 -
Transaction Round
Series C -
Proceeds Purposes
This funding will enable us to continue to move aggressively toward this goal, and demonstrates investor confidence in our technology, our business strategy, and our execution on this strategy in both the U.S. and in Brazil. -
M&A Terms
-
Venture Investor
Khosla Ventures -
Venture Investor
Kleiner Perkins Caufield & Byers -
Venture Investor
Undisclosed
